Armando Stabile

Armando Stabile

Auto-generated profile, based on publicly available information

Armando Stabile

Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2019 in Nature Reviews Urology
Verified
Journal Article
Closed access
ASArmando Stabile
Armando Stabile
FGFrancesco Giganti
Francesco Giganti
ARAndrew B. Rosenkrantz
Andrew B. Rosenkrantz
STSamir S. Taneja
Samir S. Taneja
GVGeert Villeirs
Geert Villeirs
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan

1 March 2019 in European Urology
Verified
Journal Article
Closed access
GGGiorgio Gandaglia
Giorgio Gandaglia
GPGuillaume Ploussard
Guillaume Ploussard
MVMassimo Valerio
Massimo Valerio
AMAgostino Mattei
Agostino Mattei
CFCristian Fiori
Cristian Fiori
ABAlberto Briganti
Alberto Briganti

1 September 2019 in European Urology
Verified
Journal Article
Closed access
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan
ASArmando Stabile
Armando Stabile
JNJoana B. Neves
Joana B. Neves
FGFrancesco Giganti
Francesco Giganti
MVMassimo Valerio
Massimo Valerio
CMCaroline M. Moore
Caroline M. Moore

17 March 2020 in European Urology Oncology
Verified
Journal Article
Closed access
ASArmando Stabile
Armando Stabile
FGFrancesco Giganti
Francesco Giganti
VKVeeru Kasivisvanathan
Veeru Kasivisvanathan
GGGianluca Giannarini
Gianluca Giannarini
CMCaroline M. Moore
Caroline M. Moore
JBJelle O. Barentsz
Jelle O. Barentsz

12 February 2019 in BJU International
Verified
Journal Article
Open access
PDF file
ASArmando Stabile
Armando Stabile
COClement Orczyk
Clement Orczyk
FHFeargus Hosking‐Jervis
Feargus Hosking‐Jervis
FGFrancesco Giganti
Francesco Giganti
MAManit Arya
Manit Arya
CMCaroline M. Moore
Caroline M. Moore
Objective: To report medium‐term oncological outcomes in men receiving primary focal treatment with high‐intensity focused ultrasonography ( HIFU ) for prostate cancer ( PC a). Patients and Methods: Consecutive patients with PC a treated with primary focal HIFU at two centres by six treating clinicians were assessed. Patients were submitted to either focal ablation or hemi‐ablation using HIFU (Sonablate 500). The primary objective of the study was to assess medium‐term oncological outcomes, defined as overall survival, freedom from biopsy failure, freedom from any further treatment and freedom from radical treatment after focal HIFU . The secondary objective was to evaluate the changes in pathological features among patients treated with focal HIFU over time. We also assessed the relationship between year of surgery and 5‐year retreatment probability. Results: A total of 1032 men treated between November 2005 and October 2017 were assessed . The median age was 65 years and median prostate‐specific antigen level was 7 ng/mL. The majority of patients had a Gleason score of 3 + 4 or above (80.3%). The median (interquartile range) follow‐up was 36 (14–64) months. The overall survival rates at 24, 60 and 96 months were 99%, 97% and 97%, respectively. Freedom from biopsy failure, defined as absence of Gleason 3 + 4 disease, was 84%, 64% and 54% at 24, 60 and 96 months. Freedom from any further treatment was 85%, 59% and 46% at 24, 60 and 96 months, respectively. Approximately 70% of patients who were retreated received a second focal treatment. Freedom from radical treatment was 98%, 91% and 81% at 24, 60 and 96 months. During the study period, we observed an increase in the proportion of patients undergoing focal HIFU with Gleason 3 + 4 disease and with T2 stage disease as defined by multiparametric magnetic resonance imaging. Finally, there was a reduction over time in the proportion of patients undergoing re‐treatment within 5 years of first treatment. Conclusions: Focal HIFU for PC a is a feasible therapeutic strategy, with acceptable survival and oncological results and a reduction in the 5‐year retreatment rates over the last decade. Re‐do focal treatment is a feasible technique whose functional and oncological outcomes have still to be evaluated.

1 February 2022 in European Urology Oncology
Verified
Journal Article
Closed access
ASArmando Stabile
Armando Stabile
APAntony Pellegrino
Antony Pellegrino
EMElio Mazzone
Elio Mazzone
DCDonato Cannoletta
Donato Cannoletta
MAMario de Angelis
Mario de Angelis
ABAlberto Briganti
Alberto Briganti